Rizky Farmasita Budiastuti
Universitas 17 Agustus 1945 Jakarta

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

Effectiveness of the Use of Analgetic Drugs in Sectio Caesarea (SC) Patients at RSAL Mintoharjo Atisi; Fajar Amirulah; Rizky Farmasita Budiastuti; Rangki Astiani
Jurnal FARMASIMED (JFM) Vol 8 No 2 (2026): Jurnal Farmasimed (JFM)
Publisher : Fakultas Farmasi Institut Kesehatan Medistra Lubuk Pakam

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35451/0jfgbm77

Abstract

Cesarean section (CS) is a common obstetric surgical procedure that is frequently associated with moderate to severe postoperative pain, which may delay early mobilization and prolong recovery. This study aimed to evaluate the effectiveness of analgetic use based on the type and number of analgetics on pain intensity and recovery time in post-cesarean section patients at RSAL Mintoharjo. This research was conducted as an observational analytic study with a prospective cohort design involving 80 post-CS patients. Data were collected through medical records, direct observation, and pain assessment using the Numeric Rating Scale (NRS) at 6 hours, 24 hours and on day 2 or 3 postoperatively. Statistical analysis was performed using univariate analysis, Chi-Square test, and one-way ANOVA. The results show that the type of analgesic significantly affects pain intensity at all measurement times (p < 0,05), with combination analgetic regimens providing better pain control that single analgetics. The number of analgetics does not affect pain intensity at 6 hours postoperatively but shows a significant effect at 24 hours and during follow-up interviews. Recovery time is not significantly influenced by the type or number of analgesics, with most patients discharged within three days. Patient age and comorbidities affect pain intensity, while cesarean history and smoking status do not. In conclusion, multimodal analgesia is effective for controlling acute postoperative pain following cesarean section, whereas recovery time is more strongly influenced by patient clinical factors
IN SILICO ANALYSIS OF SAGA SEED EXTRACT (Abrus precatorius L.) FOR ANDROGENIC ALOPECIA TREATMENT Dewi Rahmawati; Rizky Farmasita Budiastuti; Ashfar Kurnia
INDONESIA NATURAL RESEARCH PHARMACEUTICAL JOURNAL Vol 11, No 1 (2026)
Publisher : Fakultas Farmasi Universitas 17 Agustus 1945 Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52447/inrpj.v11i1.8773

Abstract

Androgenic alopecia (AGA) is a genetically determined hair loss condition. In men, hair loss is influenced by androgen hormones, whereas in women, androgenic alopecia is thought to be influenced by genetic factors. Currently, several drugs are used in the treatment of AGA, including 5α-reductase inhibitors, minoxidil, finasteride, and dutasteride for androgen-related disorders. However, the use of these medications may cause various undesirable side effects, such as impotence, abnormal ejaculation, decreased ejaculate volume, sexual dysfunction, gynecomastia, testicular pain, reduced muscle growth, and severe myopathy. The use of natural products as hair growth agents has been widely investigated, and several herbal extracts have been reported to be effective in the management of androgenic alopecia, one of which is saga seed extract. Saga seeds have been reported to contain campesterol, cholesterol, palmitic acid, lignoceric acid, oleic acid, linoleic acid, linolenic acid, cycloartenol, beta-amyrin, β-sitosterol, stigmasterol, trigonelline, and brassicasterol (1)). This in silico study was conducted to evaluate the potential of β-sitosterol, stigmasterol, and brassicasterol present in saga (Abrus precatorius L.) seed extract compared with the positive control, minoxidil. Molecular docking analysis using Molegro Virtual Docker based on rerank score values demonstrated that brassicasterol exhibited better binding potential than β-sitosterol, stigmasterol, and the positive control minoxidil.